Therefore, downregulating AGPAT3 expression or blocking its enzymatic product, phosphatidic acid, from binding to mTOR might be considered therapeutic approaches to overcome cisplatin chemoresistance in ovarian cancer, which has fewer side effects than other classes of mTOR inhibitors do [7]. This evidence concerns the gene MTOR and ovarian carcinoma.